Cutting Edge Spine Gains FDA Clearance of EVOL-SI Joint Fusion

Cutting Edge Spine received FDA 510(k) clearance to market the EVOL-SI sacroiliac joint fusion system.

Surface modification on the device is intended to improve osseointegration through hydrophilicity and surface chemistry, while characteristic nano-roughness mediates bioactivity that affects tissue regeneration to yield early bone...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us